Daily Roundup
After years of denying coverage, Medicare is launching a new program that could make Ozempic and Wegovy way more affordable. Plus, surprising news about what these drugs do to your liver.
Subscribe to receive the latest GLP-1 news, price alerts, and updates.
Two big moves just shook up the GLP-1 world: Hims is ditching compounded versions to team up with Novo Nordisk, while Eli Lilly quietly launched their first weight loss pill.
Foundayo is now available at pharmacies nationwide, and it's priced to compete directly with Novo's oral Wegovy at $149/month.
Eli Lilly's first oral GLP-1 pill and Novo's highest-dose Wegovy are both rolling out nationwide. Here's what you need to know about your new options.
Just days after FDA approval, Eli Lilly announced where they'll actually make their new weight loss pill—and it's a massive investment that says a lot about supply.
Eli Lilly's first oral GLP-1 for weight loss just got FDA approval in record time, but there's already drama with Novo Nordisk over who's got the better pill.
Eli Lilly's new weight loss pill just got FDA approval, and unlike other GLP-1 pills, you don't need to fast or follow strict timing rules.
Foundayo just got FDA approval and starts at $149 cash - way less than we expected. But how does it stack up against the competition?
Eli Lilly's new pill version just got approved, and it's way more convenient than the shots we're used to.
The UK just approved Wegovy for 1.2 million people to prevent heart attacks and strokes. Plus, new research shows GLP-1s might help with mental health too.
A daily pill called orforglipron might work better than Wegovy for weight loss, but nearly 60% of people taking it dealt with some pretty rough stomach issues.
Turns out Ozempic and Wegovy might be helping your body in ways doctors are just starting to understand. Plus, why you shouldn't feel bad about needing them.